¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Multiple crushing injuries, unspecified"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • multiple myositis
    ´Ù¹ß±Ù(À°)¿°
  • multiple neurofibromatosis
    ´Ù¹ß½Å°æ¼¶À¯Á¾Áõ
  • multiple neuroma
    ´Ù¹ß½Å°æÁ¾
  • multiple paramyoclonus
    ´Ù¹ß±Ù´ë¼º¹ßÀÛ
  • multiple peripheral neuritis
    ´Ù¹ß¸»ÃʽŰ濰
  • multiple personality
    ´ÙÁßÀΰÝ
  • multiple personality disorder
    ´ÙÁßÀΰÝÀå¾Ö
  • multiple pregnancy
    ´ÙÅÂÀÓ½Å, ¹µÀÓ½Å
  • multiple scattering
    ´ÙÁß»ê¶õ
  • multiple sclerosis
    ´Ù¹ß°æÈ­Áõ
  • multiple serositis
    ´Ù¹ßÀ帷¿°
  • multiple sleep latency test
    ¼ö¸éÀẹ±â¹Ýº¹°Ë»ç
  • multiple subpial transection
    ´Ù¹ß¿¬¸·¹ØÀý´Ü(¼ú)
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multiple neuroma
    ´Ù¹ß½Å°æÁ¾
  • multiple paramyoclonus
    ´Ù¹ß±Ù°£´ë°æ·Ã
  • multiple personality
    ´ÙÁßÀΰÝ
  • multiple pregnancy
    ¹µÀÓ½Å, ´ÙÅÂÀÓ½Å
  • multiple risk
    ´ÙÁßÀ§Çèµµ
  • multiple scattering
    ´ÙÁß»ê¶õ
  • multiple sclerosis
    ´Ù¹ß°æÈ­Áõ
  • multiple serositis
    ´Ù¹ßÀ帷¿°
  • multiple stratification
    ¹µÁßÃþ
  • multiple trichoepithelioma
    ¿©·¯ÅлóÇÇÁ¾
  • multiple allelic mutation
    ¹µ¸Â¼¶µ¹¿¬º¯ÀÌ
  • multiple compressed tablet
    ´ÙÁß¾ÐÃà¾Ë¾à
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
  • multiple layer tablet
    ´ÙÃþ¾Ë¾à
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multiple angiofibroma
    ´Ù¹ß¼º Ç÷°ü ¼¶À¯Á¾
  • multiple benign cystic epithelioma
    ´Ù¹ß¼º ¾ç¼º ³¶Á¾¼º »óÇÇÁ¾
  • multiple birth
    ´Ù»ê(Òýß§), ´ÙÅÂÃâ»ê(Òý÷Ãõóß§).
  • multiple bond
    ´ÙÁß°áÇÕ(ÒýñìÌ¿ùê).
  • multiple budding
    ´Ù¼öÃâ¾Æ(Òýâ¦õóä´).
  • multiple budding
    ´Ù¼öÃâ¾Æ(Òýâ¦õóä´).
  • multiple cerebral sclerosis
    ¹æ»ç ´Ù¹ß¼º ´ë³ú°æÈ­Áõ(ÒýÛ¡àõÓÞÒàÌãûùñø).
  • multiple cerebral sclerosis
    ´Ù¹ß¼º ´ë³ú°æÈ­Áõ(Û¯ÞÒ¡­ÓÞÒàÌãûùñø)
  • multiple chain
    º¹½Ä(ÜÜãÒ)»ç½½.
  • multiple characters
  • multiple compressed tablet
    ´ÙÁß¾ÐÃàÁ¤Á¦(Òýñìäâõêïüð¥).
  • multiple congenital polyposis
    ´Ù¹ß¼º ¼±Ãµ¼º(¡­à»ô¸àõ) Æú¸³Áõ(¡­ñø)
  • multiple convulsive tic
    ´Ù¹ß¼º °æ·Ã¼º(ÒýÛ¡ àõÌâÕýàõ) ƽ.
  • multiple correlation
    Áß»ó°ü( Ì¡Ë×Ë´).
  • multiple cranial nerve palsy
    ´Ù¹ß¼º ³ú½Å°æ¸¶ºñ(ÒýÛ¡àõÒàãêÌè Ýö).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
MCS malignant carcinoid syndrome; managed care system; massage of the carotid sinus; mesocaval shunt; me...
B-J protein Bence-Jones Protein
  ÀÇÀÇ; Multiple Myeloma
HCG, hCG Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó
  1. Placental Glycoprotein Hormone
&nbs...
MDII Multiple Daily Insulin Injections
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MAR Multiple Antibiotic Resistance
MAP Multiple Antigen Peptide
MAP Multiple Antigenic Peptide
MCS Multiple Chemical Sensitivities
MCS Multiple Chemical Sensitivity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • multiple myositis
    ´Ù¹ß ±Ù¿°, ´Ù¹ß¼º ±Ù¿°
  • multiple neurofibromatosis
    ´Ù¹ß ½Å°æ ¼¶À¯Á¾Áõ
  • multiple neuroma syndrome
    ´Ù¹ß¼º ½Å°æÁ¾ ÁõÈıº
  • multiple osteoma
    ´Ù¹ß¼º °ñÁ¾
  • multiple papilloma
    ´Ù¹ß¼º À¯µÎÁ¾
  • multiple petechia
    ´Ù¹ß¼º Á¡»ó ÃâÇ÷
  • multiple photoreceptor
    ´Ù¹ß¼º ±¤ ¼ö¿ëü, ´Ù¹ß¼º ±¤ ¼ö¿ë±â
  • multiple projection
    ´Ù¹ß¼º Á¶»ç
  • multiple pulmonary emboli
    ´Ù¹ß¼º Æó »öÀü
  • multiple region
    ´Ù¹ß¼º ºÎÀ§
  • multiple rough gravellike sound
    ´Ù¹ß¼ºÀÇ °ÅÄ£ ÀÚ°¥ °¡´Â ¼Ò¸®
  • multiple seborrheic keratoses
    ´Ù¹ß Áö·ç¼º °¢È­Áõ
  • multiple sinus fracture
    ´Ù¹ß¼º ºÎºñµ¿ °ñÀý
  • multiple somatic receptor
    ´Ù¹ß¼º ü ¼ö¿ëü, ´Ù¹ß¼º ü ¼ö¿ë±â
  • multiple spike
    ´Ù¹ß¼º ½ºÆÄÀÌÅ©
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
eye injuries Damage or trauma inflicted to the eye by external means. The concept includes both surface injuries and intraocular injuries.
(12 Dec 1998)
eye injuries, penetrating Deeply perforating or puncturing type intraocular injuries.
(12 Dec 1998)
facial injuries General or unspecified injuries to the soft tissue or bony portions of the face.
(12 Dec 1998)
knee injuries Injuries to the knee or the knee joint.
(12 Dec 1998)
finger injuries General or unspecified injuries involving the fingers.
(12 Dec 1998)
foot injuries General or unspecified injuries involving the foot.
(12 Dec 1998)
forearm injuries Injuries to the part of the upper limb of the body between the wrist and elbow.
(12 Dec 1998)
leg injuries General or unspecified injuries involving the leg.
(12 Dec 1998)
lightning injuries Accidental injuries caused by brief high-voltage electrical discharges during thunderstorms. Cardiopulmonary arrest, coma and other neurologic symptoms, myocardial necrosis, and dermal burns are common. Prompt treatment of the acute sequelae, including cardiopulmonary resuscitation, is indicated for survival.
(12 Dec 1998)
abortion, multiple Couples who have had 2 or more miscarriages (spontaneous abortions) have about a 5% chance that one member of the couple is carrying a chromsome translocation responsible for the miscarriages.
(12 Dec 1998)
advanced multiple-beam equalization radiography A variant of scanning equalization radiography using several X-ray beams.
(05 Mar 2000)
amyloidosis of multiple myeloma Foci of amyloidosis in mesenchymal tissues of some persons with multiple myeloma; no direct relation between amyloid and Bence Jones protein is conclusively known.
(05 Mar 2000)
cancer, multiple myeloma A bone marrow cancer involving a type of white blood cell called a plasma (or myeloma) cell. The tumour cells can form a single collection (a plasmacytoma) or many tumours (multiple myeloma). Plasma cells are part of the immune system and make antibodies. Because patients have an excess of identical plasma cells, they have too much of one type of antibody. As myeloma cells increase in number, they damage and weaken the bones, causing pain and often fractures. When bones are damaged, calcium is released into the blood leading to hypercalcaemia (excess calcium in the blood) and that causes loss of appetite, nausea, thirst, fatigue, muscle weakness, restlessness, and confusion. Myeloma cells prevent the bone marrow from forming normal plasma cells and other white blood cells important to the immune system so patients may not be able to fight infections. The cancer cells can also prevent the growth of new red blood cells, causing anaemia. Excess antibody proteins and calcium may prevent the kidneys from filtering and cleaning the blood properly Cancer, non-Hodgkin's lymphoma: A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy.
(12 Dec 1998)
chromosomes in multiple miscarriages Couples who have had more than one miscarriage (spontaneous abortion) have about a 5% chance that one member of the couple is carrying a chromsome translocation responsible for the miscarriages.
(12 Dec 1998)
miscarriages, multiple, chromosomes in Couples who have had more than one miscarriage have about a 5% chance that one member of the couple is carrying a chromsome translocation responsible for the miscarriages.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á